Thinning Revenues: Inside the $14bn Eliquis Patent Cliff

Why It Matters

The Eliquis cliff threatens to strip BMS of more than $14 bn in revenue, forcing a rapid shift in capital allocation and underscoring the need for diversification before major patent expirations. It also serves as a benchmark for how quickly blockbuster drugs can lose value once generics enter major markets.

Key Takeaways

• Eliquis sales forecast to drop from $14.4 bn to $205 m by 2031
• European generic entry begins May 2026, cutting rest‑of‑world revenue 75%
• US Medicare price cap of $231 starts Jan 2026, pre‑empting revenue loss
• BMS diversifies via $14 bn Karuna and $4.1 bn RayzeBio acquisitions
• Cobenfy, first new schizophrenia class in 50 years, launched late 2024

Pulse Analysis

The impending loss‑of‑exclusivity for Eliquis represents one of the most dramatic revenue contractions in recent pharmaceutical history. With 2025 sales projected at $14.4 bn, the drug has dominated the oral anticoagulant market for over a decade, supported by a broad prescriber base and multiple indications. The staggered patent expirations—Europe in 2026 and the United States in 2028—set the stage for a rapid, geographically sequenced erosion, illustrating how a single blockbuster can become a liability when protection lapses.

In Europe, generic competition is expected to trigger a near‑75% decline in rest‑of‑world sales by 2027, driven by tendering processes and formulary switches that quickly displace branded products. The United States, while insulated initially, will feel the impact of the Inflation Reduction Act’s Medicare price cap of $231 per 30‑day supply beginning in January 2026, curtailing revenue even before generic entry. When the 2028 patent expiry arrives, the U.S. market is projected to lose roughly half of Eliquis’s sales in a single year, with total U.S. revenues falling 99% from their 2025 peak by 2031. This rapid compression underscores the vulnerability of reliance on a single high‑margin asset.

BMS’s strategic response highlights a broader industry lesson: proactive diversification is essential. The company has invested $14 bn in Karuna Therapeutics and $4.1 bn in RayzeBio, targeting neuroscience and radiopharmaceuticals as new growth platforms. Early results are promising, with Cobenfy—a novel schizophrenia treatment—receiving FDA approval and launching in late 2024. These moves illustrate how large‑cap pharma can mitigate the financial shock of a blockbuster cliff by building a pipeline of differentiated assets, a playbook that rivals will likely emulate as other patents near expiry.